News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Ascletis Pharma-B (01672.HK) Selects ASC30_39 FDC for Clinical Development
Ascletis Pharma-B (01672.HK) announced that it has selected ASC30_39 FDC, a fixed-dose combination (FDC) of the once-daily oral small molecule GLP-1R agonist ASC30 and the once-dai...
Reset
Send
The window will close in 5 seconds
Ascletis Pharma-B (01672.HK) Selects ASC30_39 FDC for Clinical Development
Close
Recommend
4
Positive
4
Negative
1
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

Ascletis Pharma-B (01672.HK)  +0.170 (+0.956%)    Short selling $2.82M; Ratio 7.656%   announced that it has selected ASC30_39 FDC, a fixed-dose combination (FDC) of the once-daily oral small molecule GLP-1R agonist ASC30 and the once-daily oral small molecule selective amylin receptor agonist ASC39, for clinical development.

The company expects to submit an Investigational New Drug application to the US Food and Drug Administration (FDA) in 3Q26 for ASC30_39 FDC oral tablets for the treatment of obesity. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-10 16:25.)



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.